These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 11981823)

  • 1. The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane attack complex formation on normal peripheral human B cells.
    Nielsen CH; Pedersen ML; Marquart HV; Prodinger WM; Leslie RG
    Eur J Immunol; 2002 May; 32(5):1359-67. PubMed ID: 11981823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes.
    Nielsen CH; Marquart HV; Prodinger WM; Leslie RG
    Immunology; 2001 Dec; 104(4):418-22. PubMed ID: 11899427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneous complement activation on human B cells results in localized membrane depolarization and the clustering of complement receptor type 2 and C3 fragments.
    Løbner M; Leslie RG; Prodinger WM; Nielsen CH
    Immunology; 2009 Sep; 128(1 Suppl):e661-9. PubMed ID: 19740327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
    Marquart HV; Svehag SE; Leslie RG
    J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.
    Olesen EH; Johnson AA; Damgaard G; Leslie RG
    Immunology; 1998 Feb; 93(2):177-83. PubMed ID: 9616366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) cooperate in the binding of hydrolyzed complement factor 3 (C3i) to human B lymphocytes.
    Leslie RG; Prodinger WM; Nielsen CH
    Eur J Immunol; 2003 Dec; 33(12):3311-21. PubMed ID: 14635039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The classical and alternative pathways of complement activation play distinct roles in spontaneous C3 fragment deposition and membrane attack complex (MAC) formation on human B lymphocytes.
    Leslie RG; Nielsen CH
    Immunology; 2004 Jan; 111(1):86-90. PubMed ID: 14678202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of complement receptor type 1 (CD35) and decay-accelerating factor (CD55) on complement receptor type 2- (CD21) mediated alternative pathway activation by B cells.
    Leslie RG
    Immunology; 1999 Jul; 97(3):371-3. PubMed ID: 10447756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL.
    Delibrias CC; Fischer E; Bismuth G; Kazatchkine MD
    J Immunol; 1992 Aug; 149(3):768-74. PubMed ID: 1386093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells.
    Kozono Y; Abe R; Kozono H; Kelly RG; Azuma T; Holers VM
    J Immunol; 1998 Feb; 160(4):1565-72. PubMed ID: 9469411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematin promotes complement alternative pathway-mediated deposition of C3 activation fragments on human erythrocytes: potential implications for the pathogenesis of anemia in malaria.
    Pawluczkowycz AW; Lindorfer MA; Waitumbi JN; Taylor RP
    J Immunol; 2007 Oct; 179(8):5543-52. PubMed ID: 17911641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV.
    Delibrias CC; Kazatchkine MD; Fischer E
    Scand J Immunol; 1993 Aug; 38(2):183-9. PubMed ID: 8346417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of complement receptor type 1 (CR1, CD35) in determining the cellular distribution of opsonized immune complexes between whole blood cells: kinetic analysis of the buffering capacity of erythrocytes.
    Nielsen CH; Matthiesen SH; Lyng I; Leslie RG
    Immunology; 1997 Jan; 90(1):129-37. PubMed ID: 9038723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement activation by malignant B cells from patients with chronic lymphocytic leukaemia (CLL).
    Marquart HV; Grønbaek K; Christensen BE; Svehag SE; Leslie RG
    Clin Exp Immunol; 1995 Dec; 102(3):575-81. PubMed ID: 8536375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease.
    Kulik L; Hewitt FB; Willis VC; Rodriguez R; Tomlinson S; Holers VM
    Mol Immunol; 2015 Feb; 63(2):479-88. PubMed ID: 25457881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
    Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
    Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE).
    Marquart HV; Svendsen A; Rasmussen JM; Nielsen CH; Junker P; Svehag SE; Leslie RG
    Clin Exp Immunol; 1995 Jul; 101(1):60-5. PubMed ID: 7621593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
    Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
    J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of complement receptors 1 and 2 on mouse splenic B cells using flow cytometry.
    Donius LR; Weis JH
    Methods Mol Biol; 2014; 1100():305-10. PubMed ID: 24218269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deficiencies of human C3 complement receptors type 1 (CR1, CD35) and type 2 (CR2, CD21).
    Kazatchkine MD; Fearon DT
    Immunodefic Rev; 1990; 2(1):17-41. PubMed ID: 2164822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.